Award

The Guardant360 assay kits

THE ROYAL MARSDEN NHS FOUNDATION TRUST

This public procurement record has 1 release in its history.

Award

08 Jun 2022 at 13:30

Summary of the contracting process

The procurement process involves the Royal Marsden NHS Foundation Trust, seeking to acquire the Guardant360 assay kits, classified under the Pathology dissection instruments and supplies category. The process is currently complete, with an active contract awarded to Guardant Health, following a limited procurement method that was negotiated without the publication of a contract notice. The contract, valued at £1,638,336, was signed on 15th October 2021. The delivery of the kits is to take place within the UK, fulfilling a partnership agreement essential for the Trust's services.

This tender presents significant business growth opportunities, particularly for companies specialising in medical supplies and diagnostic technologies. Businesses equipped to supply unique products like the Guardant360 assay kits, or those capable of providing specialised services in partnership with established suppliers, may find themselves well-positioned to compete in future tenders. Notably, this contract highlights the importance of unique supply chains in the healthcare sector, making it critical for potential bidders to establish strong partnerships and offer innovative solutions tailored to the needs of buyers like the Royal Marsden NHS Foundation Trust.

Find more tenders on our Open Data Platform.
How relevant is this notice?

D3 Tenders Premium

Win More Public Sector Contracts

AI-powered tender discovery, pipeline management, and market intelligence — everything you need to grow your public sector business.

Notice Title

The Guardant360 assay kits

Notice Description

The Guardant360 assay kits are required to deliver the Trust's partnership agreement with Guardant Health. This is the only kit that can be used to deliver this and is included in the contract requirements with Guardant.

Lot Information

Lot 1

The G360 assay designed by Guardant Health is run using Guardant's proprietary sequencing reagents and bioinformatics pipeline and as such an alternative sequencing assay cannot be used. This is direct award to Guardant Health due to designed kits which are needed to run the Guardant assay.

Procurement Information

There is only one supplier i.e. Guardant, we have to use their kit to run the Guardant assay, there is no alternative. We have formed a partnership with Guardant to provide this service. Guardant360 CDx utilizes circulating tumour DNA (ctDNA) from plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes (BCTs). Guardant360(r) CDx is a qualitative custom designed next generation sequencing-based in vitro diagnostic device that uses targeted high throughput hybridization-based capture technology for detection of single nucleotide variants (SNVs), insertions and deletions (indels) in 55 genes, copy number amplifications (CNAs) in two (2) genes, and fusions in four (4) genes.

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-03444c
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/015783-2022
Current Stage
Award
All Stages
Award

Procurement Classification

Notice Type
Award Notice
Procurement Type
Standard
Procurement Category
Goods
Procurement Method
Limited
Procurement Method Details
Negotiated without publication of a contract notice
Tender Suitability
Not specified
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products


CPV Codes

33910000 - Pathology dissection instruments and supplies

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
£1,638,336 £1M-£10M

Notice Dates

Publication Date
8 Jun 20223 years ago
Submission Deadline
Not specified
Future Notice Date
Not specified
Award Date
14 Oct 20214 years ago
Contract Period
Not specified - Not specified
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Not Specified
Awards Status
Active
Contracts Status
Active

Contracting Authority (Buyer)

Main Buyer
THE ROYAL MARSDEN NHS FOUNDATION TRUST
Contact Name
chelwest.tenders@nhs.net
Contact Email
chelwest.tenders@nhs.net
Contact Phone
Not specified

Buyer Location

Locality
LONDON
Postcode
SW10 0XD
Post Town
South West London
Country
England

Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI3 Inner London - West
Small Region (ITL 3)
TLI33 Kensington & Chelsea and Hammersmith & Fulham
Delivery Location
Not specified

Local Authority
Hammersmith and Fulham
Electoral Ward
Sands End
Westminster Constituency
Chelsea and Fulham

Supplier Information

Number of Suppliers
1
Supplier Name

GUARDANT HEALTH

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

Download

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-03444c-2022-06-08T14:30:18+01:00",
    "date": "2022-06-08T14:30:18+01:00",
    "ocid": "ocds-h6vhtk-03444c",
    "initiationType": "tender",
    "tender": {
        "id": "ocds-h6vhtk-03444c",
        "legalBasis": {
            "id": "32014L0024",
            "scheme": "CELEX"
        },
        "title": "The Guardant360 assay kits",
        "status": "complete",
        "classification": {
            "scheme": "CPV",
            "id": "33910000",
            "description": "Pathology dissection instruments and supplies"
        },
        "mainProcurementCategory": "goods",
        "description": "The Guardant360 assay kits are required to deliver the Trust's partnership agreement with Guardant Health. This is the only kit that can be used to deliver this and is included in the contract requirements with Guardant.",
        "lots": [
            {
                "id": "1",
                "description": "The G360 assay designed by Guardant Health is run using Guardant's proprietary sequencing reagents and bioinformatics pipeline and as such an alternative sequencing assay cannot be used. This is direct award to Guardant Health due to designed kits which are needed to run the Guardant assay.",
                "awardCriteria": {
                    "criteria": [
                        {
                            "type": "price"
                        }
                    ]
                },
                "hasOptions": false
            }
        ],
        "items": [
            {
                "id": "1",
                "deliveryAddresses": [
                    {
                        "region": "UK"
                    }
                ],
                "relatedLot": "1"
            }
        ],
        "procurementMethod": "limited",
        "procurementMethodDetails": "Negotiated without publication of a contract notice",
        "coveredBy": [
            "GPA"
        ],
        "procurementMethodRationaleClassifications": [
            {
                "scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
                "id": "D_ARTISTIC",
                "description": "The works, supplies or services can be provided only by a particular economic operator due to procurement aiming at the creation or acquisition of a unique work of art or artistic performance"
            }
        ],
        "procurementMethodRationale": "There is only one supplier i.e. Guardant, we have to use their kit to run the Guardant assay, there is no alternative. We have formed a partnership with Guardant to provide this service. Guardant360 CDx utilizes circulating tumour DNA (ctDNA) from plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes (BCTs). Guardant360(r) CDx is a qualitative custom designed next generation sequencing-based in vitro diagnostic device that uses targeted high throughput hybridization-based capture technology for detection of single nucleotide variants (SNVs), insertions and deletions (indels) in 55 genes, copy number amplifications (CNAs) in two (2) genes, and fusions in four (4) genes."
    },
    "awards": [
        {
            "id": "015783-2022-1",
            "relatedLots": [
                "1"
            ],
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-54968",
                    "name": "Guardant Health"
                }
            ]
        }
    ],
    "parties": [
        {
            "id": "GB-FTS-2920",
            "name": "The Royal Marsden NHS Foundation Trust",
            "identifier": {
                "legalName": "The Royal Marsden NHS Foundation Trust"
            },
            "address": {
                "streetAddress": "Unit G3, Harbour Yard, Chelsea Harbour",
                "locality": "London",
                "region": "UKI33",
                "postalCode": "SW10 0XD",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "name": "chelwest.tenders@nhs.net",
                "email": "chelwest.tenders@nhs.net"
            },
            "roles": [
                "buyer",
                "reviewBody",
                "reviewContactPoint"
            ],
            "details": {
                "url": "https://www.royalmarsden.nhs.uk",
                "buyerProfile": "https://www.royalmarsden.nhs.uk",
                "classifications": [
                    {
                        "scheme": "TED_CA_TYPE",
                        "id": "BODY_PUBLIC",
                        "description": "Body governed by public law"
                    },
                    {
                        "scheme": "COFOG",
                        "id": "07",
                        "description": "Health"
                    }
                ]
            },
            "additionalContactPoints": [
                {
                    "email": "chelwest.tenders@nhs.net"
                }
            ]
        },
        {
            "id": "GB-FTS-54968",
            "name": "Guardant Health",
            "identifier": {
                "legalName": "Guardant Health"
            },
            "address": {
                "streetAddress": "505 Penobscot Drive Redwood City CA 94063 United States",
                "locality": "Redwood City",
                "region": "US",
                "postalCode": "CA 94063",
                "countryName": "United States"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-497",
            "name": "The High Court",
            "identifier": {
                "legalName": "The High Court"
            },
            "address": {
                "streetAddress": "Strand",
                "locality": "London",
                "postalCode": "WC2A 2LL",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "email": "generaloffice@administrativecourtoffice.justice.gov.uk"
            },
            "roles": [
                "mediationBody"
            ],
            "details": {
                "url": "https://www.gov.uk/courts-tribunals"
            }
        }
    ],
    "buyer": {
        "id": "GB-FTS-2920",
        "name": "The Royal Marsden NHS Foundation Trust"
    },
    "contracts": [
        {
            "id": "015783-2022-1",
            "awardID": "015783-2022-1",
            "status": "active",
            "value": {
                "amount": 1638336,
                "currency": "GBP"
            },
            "dateSigned": "2021-10-15T00:00:00+01:00"
        }
    ],
    "language": "en"
}